The FDA approval of the first wave of biosimilars cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to important medications. There is a significant market opportunity ahead for biosimilar drugmakers; by 2020, leading biologic medicines worth more than $80 billion global annual sales will lose their patent protections, and biosimilars is the largest area for potential growth in the biotech sector. But with great rewards, there are also great risks that must be considered. In contrast to Europe, this is still an uncharted territory for the US market, and

Date : 18th September 2017 to 19th September 2017

Place : United States, Boston

Website :https://www.eventbrite.com/e/biosimilar-market-access-and-commercialization-strategies-summit-exl-tickets-34262177094?aff=NDT

Contact Person:Paula Edwards

Description:

The FDA’s approval of the first wave of biosimilars cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to important medications. There is a significant market opportunity ahead for biosimilar drugmakers; by 2020, leading biologic medicines worth more than $80 billion global annual sales will lose their patent protections, and biosimilars is the largest area for potential growth in the biotech sector. But with great rewards, there are also great risks that must be considered. In contrast to Europe, this is still an uncharted territory for the US market, and

The FDA approval of the first wave of biosimilars cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to important medications. There is a significant market opportunity ahead for biosimilar drugmakers; by 2020, leading biologic medicines worth more than $80 billion global annual sales will lose their patent protections, and biosimilars is the largest area for potential growth in the biotech sector. But with great rewards, there are also great risks that must be considered. In contrast to Europe, this is still an uncharted territory for the US market, and will be held in Boston,United States on date 2017-09-19

---

Deadline for abstracts/proposals : 8th September 2017

Keynote Speakers :

Conference Highlights :Explore factors to consider before developing biosimilars — improve your chances on the road to approval and commercial success Hear best practices and case studies for a successful biosimilar product strategy from its conception to execution Stay up to date with FDA guidances and other regulatory guidelines and join the debate on nonproprietary naming of biological and biosimilar products Navigate biosimilar policies, regulations and compliance issues under the new administration

Venue :Boston, MA, United States

Check the event website for more details.